Should I be concerned about pancreatitis on Wegovy?
Wegovy carries a small risk of pancreatitis, as noted in clinical trials, prescribing information, and real-world evidence. People with certain risk factors, such as a history of pancreatitis or gallbladder disease, need careful evaluation before starting or continuing the medication. Stop Wegovy and contact your healthcare provider if pancreatitis is suspected.
Key points:
- Wegovy acts on pancreatic cells and has been associated with cases of acute pancreatitis.
- Regulatory bodies in the UK monitor this risk through schemes like Yellow Card for GLP-1 medicines including Wegovy.
- Studies show mixed evidence, with some indicating no overall increased risk and others linking recent use to higher odds.
- Patients with prior pancreatitis or related conditions require risk-benefit assessment.
This text has been fact-checked for accuracy by Sorin Romaniuc, Pharmacist at medino.